Aplicación de las guías de prevención secundaria de fractura osteoporótica y del índice FRAX en una cohorte de pacientes con fractura por fragilidad

Naranjo, Antonio; Ojeda Bruno, Soledad; Francisco Hernández, Félix; Erausquin, Celia; Rúa Figueroa, Iñigo; Rodríguez Lozano, Carlos.
Med. clín (Ed. impr.) ; 136(7): 290-292, mar. 2011. tab
Artículo en Español | IBECS (España) | ID: ibc-87144

Documentos relacionados

  1. Efficacy and safety of alendronic acid in the treatment of osteoporosis in children
  2. A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men.
  3. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.
  4. Sustained delivery of alendronate by engineered collagen scaffold for the repair of osteoporotic bone defects and resistance to bone loss.
  5. COMPARATIVE BIOAVAILABILITY ANALYSIS OF ORAL ALENDRONATE SODIUM FORMULATIONS IN PAKISTAN.
  6. Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018.
  7. Development and validation of a novel sensitive UV-direct capillary electrophoresis method for quantification of alendronate in release studies from biomaterials.
  8. Alendronate for the treatment of osteoporosis in men.
  9. Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.
  10. Alendronate: an update of its use in osteoporosis.